Ketamine for Treatment-Resistant Depression: The Fastest-Acting Antidepressant

What Makes Ketamine Different from Standard Antidepressants?

Most antidepressants prescribed today, including SSRIs and SNRIs, work by adjusting serotonin or norepinephrine levels in the brain. They can be effective, but they share two frustrating limitations. They take weeks to produce noticeable benefit, and for roughly a third of people with major depression, they do not work well even after several attempts. That group is what clinicians mean by treatment-resistant depression, usually defined as an inadequate response to at least two adequate courses of antidepressant medication.

Ketamine takes a different route. Rather than nudging serotonin, it acts on glutamate, the most abundant excitatory chemical messenger in the brain. Specifically, ketamine blocks a receptor called the NMDA receptor, and that single action sets off a cascade of downstream effects that appear to restart the brain’s capacity to form new connections. This is why ketamine can help people for whom serotonin-based drugs have failed. It is working through an entirely separate mechanism.

The speed is the part that surprises people most. A conventional antidepressant asks you to wait a month or more to find out whether it will help. Ketamine often produces measurable improvement the same day.

How Fast Does Ketamine Actually Work?

The rapid onset is not marketing language, it is one of the most consistently replicated findings in modern psychiatry. In a two-site randomized controlled trial published in the American Journal of Psychiatry, a single intravenous infusion of ketamine improved depression severity in 64 percent of treatment-resistant patients within 24 hours, measured against an active placebo (the sedative midazolam) rather than a saline drip. Using an active control matters, because it rules out the possibility that people simply felt better from being sedated.

For comparison, standard antidepressants are generally evaluated over six to eight weeks. The contrast in timescale is the entire reason ketamine attracted serious clinical attention. When someone is in an acute depressive crisis, the difference between hours and weeks is not academic.

There is an important caveat that responsible providers always name. The benefit from a single infusion is real but often short-lived. Symptoms can return within days to a couple of weeks. This is why ketamine is almost never delivered as a one-time event. It is structured as a series of sessions, frequently a course of six infusions over two to three weeks, followed by a maintenance plan tailored to the individual.

What Do the Clinical Trials Show?

The evidence base here is stronger than for most psychedelic-adjacent treatments, which is worth stating plainly. Ketamine has been studied in well-controlled trials, and the results have held up across independent research groups.

One of the most significant recent studies is the ELEKT-D trial, published in the New England Journal of Medicine in 2023. It was the largest head-to-head comparison of ketamine and electroconvulsive therapy (ECT) for nonpsychotic treatment-resistant depression, enrolling 403 patients across five academic medical centers. ECT has long been considered the most effective option for severe, resistant depression, so this was a demanding benchmark. Ketamine was found to be noninferior to ECT, meaning it performed at least as well on the primary measure of treatment response. In that trial, 55 percent of the ketamine group responded compared with 41 percent of the ECT group, and ketamine patients reported fewer memory-related side effects.

Researchers have also begun to confirm the biological story behind the clinical results. A 2023 randomized controlled trial using brain imaging found measurable changes in gray matter structure just 24 hours after a single ketamine infusion, consistent with the neuroplasticity mechanism observed in animal studies. In plain terms, the brain scans showed physical signs of the rewiring that the theory predicts, on the same rapid timescale as the mood improvement.

What we can say with confidence is that ketamine produces rapid, clinically meaningful reductions in depression for a substantial share of people who have exhausted other options. What remains an active area of research is how to make those gains last.

Ketamine, Esketamine, and Spravato: What Is the Difference?

This is where terminology causes real confusion, so it is worth slowing down. Ketamine is a single molecule that exists as two mirror-image forms. Esketamine is one of those forms, isolated and developed as a pharmaceutical nasal spray under the brand name Spravato.

The distinction matters for access. Spravato is FDA-approved. It received initial approval in 2019 for treatment-resistant depression when used alongside an oral antidepressant, and in January 2025 the FDA expanded that approval to allow Spravato as a standalone (monotherapy) treatment. Because it is approved, Spravato is administered in certified medical settings and is more likely to be covered by insurance.

Racemic ketamine, the original form that contains both mirror-image molecules, is not FDA-approved specifically for depression. It is used “off-label,” which is legal and common, typically delivered as an intravenous infusion in a clinic. Off-label use is not a red flag on its own. Much of medicine operates this way. It does mean the setting, dosing, and oversight vary more from provider to provider, which is exactly why the quality of the clinical environment matters.

Who Is Ketamine For, and Who Should Be Cautious?

Ketamine is generally considered for adults with moderate to severe depression who have not responded to at least two standard antidepressants. It has drawn particular interest for situations where speed is critical, including acute suicidal thinking, though addressing suicidality specifically requires a clinical team and is beyond what any single treatment resolves on its own.

It is not appropriate for everyone. People with certain cardiovascular conditions, a history of psychosis, or active substance use disorders involving dissociatives need careful evaluation, and in some cases ketamine will be ruled out. Because ketamine can be misused and carries its own dependence risk, the structure around it (medical screening, supervised administration, and a defined treatment arc rather than open-ended access) is not bureaucratic caution. It is central to using the medicine safely. A thorough screening process is designed to surface exactly these concerns before anyone begins. For a fuller picture of what disqualifies or delays candidacy, our guide to who should pause before pursuing psychedelic therapy covers the medical and psychiatric factors in detail.

Preparation also shapes outcomes more than most people expect. Ketamine produces a dissociative state, a sense of distance from one’s ordinary experience, and how someone enters that state influences what they get from it. A grounded, well-prepared session in a supportive setting is a different experience from an unprepared one. Our guide to ketamine therapy preparation explains why the work done before the session is a functional part of the treatment, not a formality.

How Does Ketamine Compare to Other Options?

For treatment-resistant depression specifically, the realistic comparison is not ketamine versus an SSRI. Someone considering ketamine has usually already tried and failed several antidepressants. The meaningful comparisons are ketamine, ECT, and (in the two states where it is legally available in a regulated therapeutic setting) psilocybin.

Against ECT, the ELEKT-D trial suggests ketamine is a comparably effective option with a lighter side-effect profile for many people, particularly around memory. Against psilocybin, the two work through different mechanisms and suit different circumstances. Psilocybin is delivered as a single or small number of deep, guided sessions, while ketamine is more often a repeated, shorter-acting intervention. For a direct look at how these two compare on mechanism, setting, legality, and evidence, our breakdown of psilocybin versus ketamine therapy lays out the trade-offs.

The right choice depends on the person, their medical history, their access, and what they are trying to address. That is a decision to make with qualified clinical support, not from a blog post.